Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06108726 | A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | Phase 2 | 16 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06104709 | Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma | unknown | — | 10 | China-Japan Friendship HospitalOTHER | 0 | Oct 27, 2023 |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06081777 | Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer(MRDinS3LC) | unknown | — | 65 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04737382 | Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.(OSIRIS) | unknown | N/A | 200 | The Netherlands Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06068088 | Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)(LUNGDIET) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 5, 2023 | clinicaltrials |
| NCT06065813 | Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy(ROME) | unknown | Phase 2 | 400 | Fondazione per la Medicina PersonalizzataOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04726215 | Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | unknown | Phase 2 | 50 | CellSight Technologies, Inc.INDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05273047 | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC(LungKG12Ci) | unknown | — | 458 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04074993 | Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays | unknown | Phase 2 | 35 | JI-YOUN HANOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05128630 | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.(DEDALUS) | unknown | Phase 2 | 45 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05999214 | 99mTc-H7ND SPECT/CT Imaging in NSCLC | unknown | N/A | 150 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06018688 | Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. | unknown | Phase 2 | 44 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| NCT05418660 | Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC(I-STOP) | unknown | — | 300 | University of Milano BicoccaOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06031597 | Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | unknown | Phase 3 | 105 | Zhejiang Cancer HospitalOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT03334864 | Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG) | unknown | — | 5,000 | Peking Union Medical College HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05338619 | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy(PLATINUM) | unknown | Phase 2 | 77 | Sung Yong LeeOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06020989 | Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy(CHAMELEON) | unknown | Phase 2 | 129 | Yonsei UniversityOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06020352 | The Efficacy and Safety of KN046 Combined With Axitinib | unknown | Phase 2 / Phase 3 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT06014450 | Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study | unknown | N/A | 144 | Guizhou Medical UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05869162 | Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI | unknown | Phase 2 | 153 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06010277 | Folinic Acid for Prevention of Pemetrexed-induced Toxicity(FLEX) | unknown | Phase 4 | 50 | Amphia HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05892237 | CIETAI and Sequential Radiotherapy in Squamous Lung Cancer | unknown | Phase 2 | 50 | Dong WangOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05347628 | Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 91 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03215693 | X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | unknown | Phase 2 | 152 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05991895 | Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer | unknown | — | 5,000 | Jinming YuOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05102214 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05978401 | Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 152 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05974007 | Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC(NeoR-World) | unknown | — | 1,500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05962021 | Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation | unknown | Phase 2 | 126 | Peking University People's HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05648955 | Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment(ALLIES) | unknown | Early Phase 1 | 118 | Nutricia ResearchINDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05965102 | Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer | unknown | Phase 1 | 31 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT05794711 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05794724 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05094882 | Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010) | unknown | — | 500 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05932264 | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05925738 | Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer | unknown | — | 1,500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05925751 | Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05921474 | Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors(SABR-DETECT) | unknown | — | 100 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05919641 | LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT(LIVELUNG) | unknown | — | 130 | Odense University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05910034 | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | unknown | Phase 2 | 132 | Fudan UniversityOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05489731 | VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer(VIC-1911) | unknown | Phase 1 | 72 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.OTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05900219 | Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study | unknown | Phase 2 | 75 | Shanghai Kechow Pharma, Inc.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05527808 | A Single-arm Exploratory Study of Neoadjuvant Therapy | unknown | N/A | 28 | Jun LiuOTHER | 1 | Jun 8, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 31, 2023source: clinicaltrials